Table 3. A Comparison of Bleomycin/Vincristine versus Vincristine Monotherapy on the Probability of Tumor Improvement at 40–42 Weeks^*.

		Risk Ratio	95% Confidence Interval
A. Comparison of Tumor Improvement versus non-improvement (stable, progressive) (N = 346)
Unadjusted		2.25	(1.47, 3.44)
Adjusted		2.46	(1.57, 3.86)
B. Comparison of tumor improvement versus non-improvement (stable, progressive, dead, default) (N = 354)
Unadjusted		1.88	(1.16, 3.03)
Adjusted		2.06	(1.24, 3.41)
C. Comparison of tumor improvement versus non-improvement (stable, progressive, dead, default, missing) (N = 449)
Unadjusted		1.42	(0.81, 2.51)
Adjusted		1.48	(0.85, 2.60)

*Comparison of the probability of tumor improvement versus tumor non-improvement among patients on Bleomycin/Vincristine versus those on Vincristine monotherapy. In model (A), only patients with recorded tumor information are included. In model (B), all patients who were dead or lost/defaulted were also included and categorized with tumor non-improvement. In model C, all patients who were dead, lost/defaulted, or missing were classified as having tumor non-improvement. All adjusted models control for age and baseline CD4 count.